- Research Article
- 10.1016/s0140-6736(26)00543-x
Understanding where people with tuberculosis seek care to serve them better.
- Mar 20, 2026
- Lancet (London, England)
- Charity Oga-Omenka + 4 more +4
Publications from 2021 to 2026
Showing 10 of 107 papers
Understanding where people with tuberculosis seek care to serve them better.
Primary mucinous adenocarcinoma of the urethra: a diagnostic conundrum – two case reports and literature review
Primary mucinous adenocarcinoma (PMAC) of the urethra is an exceptionally rare subtype of primary urethral carcinoma, with limited published data to guide diagnosis or treatment. Most literature consists of isolated case reports, and the non-specific presentation often delays diagnosis. This report presents two further cases and a review of the literature with a view to expand current understanding. We report two cases of PMAC. The first involves a 67-year-old male with progressive lower urinary tract symptoms initially treated as benign prostatic hyperplasia. Histology following a transurethral resection of the prostate revealed invasive mucinous adenocarcinoma with enteric features. He underwent radical prostatectomy, chemotherapy and radiotherapy for metastatic disease. The second case is a 52-year-old female with chronic urinary symptoms and a urethral mass initially misattributed to being from gynaecological origin. However, a biopsy later confirmed mucinous adenocarcinoma of the urethra. She underwent chemotherapy and radiotherapy, with partial response, but later developed further metastatic spread and is now undergoing palliative chemotherapy. PMAC is aggressive, often presents with non-specific urinary symptoms and lacks standardised diagnostic or treatment protocols. These cases highlight the importance of early detection through biopsies, immunohistochemical analysis and a multidisciplinary approach. Broader awareness and further reporting of cases are essential to develop evidence-based diagnostic and treatment guidelines for this rare malignancy.
Read moreLost to follow-up while undergoing intravitreal injection therapy: barriers to adherence in a real-world setting.
Intravitreal anti‑VEGF therapy is effective, yet real‑world outcomes are limited by non persistence. We investigated patient‑reported reasons for discontinuation under pro-re-nata therapy protocol. This ambispective real-world study at a German eye hospital evaluated patients receiving intravitreal therapy for diabetic macular edema (DME), retinal vein occlusion (RVO), or neovascular age related macular degeneration (nAMD) using the pro re nata (PRN) protocol. Patient records were reviewed, and those meeting lost to follow up (LTFU) criteria (no injections or visits within 3 months) were contacted via written letter and phone. When patients were reached surveys to assess reasons for LTFU, perceived treatment burden, mobility, and comorbidities were completed. Of 657 cases, 347 (52.8%) met the LTFU- criteria, 25 of which were medically indicated. Despite multiple attempts, contact and data collection was successful for only 39 patients (response rate: 12%), major part was unwilling or unable to participate. The most common reasons for discontinuation were subjective lack of treatment need (56%), perception of being “fully treated” (33%), fear of injections (26%), travel difficulties (28%), and time burden (15%). Despite these barriers, 52% of patients reported that the treatment was “not burdensome at all,” while 3 patients (8%) continued therapy elsewhere. In this exploratory, single-centre cohort, a significant portion of patients had effectively disengaged from IVI care and were unreceptive to delayed outreach. Outcome-related perceptions and organizational hurdles were key, actionable barriers. Future strategies to improve adherence should focus on proactive follow-ups shortly after therapy discontinuation.
Read moreDigital twins in urology: a vision for the future of urological practice
Digital twins, dynamic, patient-specific virtual replicas of physical systems are gaining momentum across various medical fields. Their capacity to simulate and predict biological behavior offers unprecedented opportunities for personalized care. While their utility has been demonstrated in oncology, their application in urology remains nascent, and there is still a significant gap in literature findings. This review explores the theoretical framework, current evidence, and future potential of digital twins technology in managing urological conditions such as urolithiasis, benign prostatic hyperplasia (BPH), and nonmuscle invasive bladder cancer. A narrative literature review, guided by SANRA criteria, was conducted using PubMed and Scopus databases to identify relevant studies on the application of digital twins in healthcare, with a focus on urology and related fields. Additional sources from AI, imaging, and computational modelling were incorporated to support technological and theoretical concepts. Real-world use cases and clinical scenarios were constructed to illustrate the conceptual application of digital twins in endourology. Although limited in number, preliminary studies have shown promising results in uro-oncology, particularly for prostate and renal cancers. No models have yet been developed for benign urological diseases. Hypothetical applications in endourology include personalized procedural planning, dynamic follow-up, prediction of obstruction or recurrence, and real-time intraoperative guidance. Integration of imaging, functional data, and AI algorithms could create continuously adaptive simulations to support decision-making and improve treatment outcomes. However, barriers such as data complexity, cost, lack of validation frameworks, and clinician trust persist. Digital twins hold transformative potential for the future of urology, promising to personalize care across diagnosis, treatment, and surveillance. While the path to clinical integration is challenged by technical, ethical, and infrastructural hurdles, collaborative efforts and real-world validation studies are critical to realizing their full potential in clinical practice.
Read moreTargeting tau in Alzheimer’s Disease: rationale, approach and challenges
Alzheimer’s Disease (AD) is the most common neurodegenerative disorder and the leading cause of dementia characterised by the accumulation of beta amyloid (Aβ) plaques and neurofibrillary tangles (NFT). Several monoclonal antibodies against amyloid in early AD have shown the utility of reducing brain amyloid in large phase 3 studies, resulting in modest clinical benefit. To further slow, or even halt disease progression, targeting additional pathobiological pathways is likely to be necessary. In this review, we aim to appraise the scientific rationale for targeting tau in AD. The burden of tau pathology is correlated with disease severity and its role in AD progression is complex, involving synapse dysfunction, neuronal loss, neuroinflammation and autophagy impairment. Evidence suggests that hypersecretion, post-translational modifications and aggregation propensity, dependent and independent of amyloid, are also linked to neurodegeneration. We review the therapeutic agents in development including tau synthesis modifiers, active and passive immunotherapies, post-translational modifiers and aggregation inhibitors. Finally, we consider the available biomarker tools for patient selection and drug effectiveness evaluation, and we identify key knowledge gaps that future novel biomarkers might address to make clinical trials of tau therapies more likely to succeed.
Read moreIdentification of difficult airways in critical care units (ID-ACCT): a multicentre, survey-based prospective observational study.
Airway-related complications are common in ICUs and cause serious patient harm. We determined the prevalence of known and predicted difficult airways in ICU patients in the UK, assessed whether these patients are identifiable as at risk, and evaluated the presence of airway management plans through local investigator-led bedside assessment. We conducted a prospective, multicentre, observational study in 106 UK ICUs. Adult patients without treatment escalation plans precluding artificial airway insertion were included. Patients with known difficult airways (defined as difficulty in face-mask ventilation, laryngoscopy, or intubation) or predicted difficult airways (defined as BMI ≥30 kg m-2, tracheostomy in situ, pathology or recent surgery affecting airway management, or modified MACOCHA score ≥3) were evaluated. Presence of clear identification and airway management planning for at-risk patients was assessed by local investigators. Amongst 1965 patients, 872 (44.4%) had an artificial airway in situ (tracheal tube n=639 [73.3%], tracheostomy tube n=233 [26.7%]). Among 1519 patients with intubation details, 244 (16.1%) had a known difficult airway (difficult face-mask ventilation n=32 [2.1%], laryngoscopy n=37 [2.4%], intubation n=182 [12.0%]). In this population, 70 (28.7%) were clearly identifiable to investigators, and 75 (30.7%) had airway management plans. Excluding patients with a known difficult airway, 922 patients had predicted difficult airway management, of whom 125 (13.6%) were clearly identifiable and 181 (19.6%) had airway management plans. Known and predicted difficult airways are common in UK ICU patients, but these at-risk patients are often not clearly identifiable to healthcare professionals.
Read moreEndoscopic retrograde cholangiopancreatography in pediatric and adult populations: 17-year experience from Pakistan with trends, complications, and global comparison
BACKGROUNDEndoscopic retrograde cholangiopancreatography (ERCP) is an essential diagnostic and therapeutic procedure for pancreatobiliary disorders. However, few large-scale studies from South Asia have examined long-term ERCP outcomes, particularly using established quality benchmarks.AIMTo evaluate ERCP indications, success rates, complications, and quality performance at a high-volume tertiary care center in Pakistan over a 17-year period.METHODSThis retrospective study analyzed 13215 ERCP procedures performed between 2006 and 2023. Data included demographics, indications, cannulation rates, complications, and pediatric cases. Findings were assessed against American Society of Gastroenterology/European Society of Gastrointestinal Endoscopy quality indicators.RESULTSBiliary ERCP accounted for 93.1% of procedures; choledocholithiasis was the most common indication (40%). Cannulation success was 93.9% for biliary and 94.2% for pancreatic ERCP. Pediatric ERCP comprised 4% of cases, mostly for stones and chronic pancreatitis. Bleeding (1.7%) and post-ERCP pancreatitis (2.3%) were the most frequent complications. Performance met or exceeded most American Society of Benchmarks.CONCLUSIONThis study offers insight into nearly two decades of ERCP practice within a public sector hospital. Our experience echoes the quality and efficiency of ERCP not previously available in Pakistan. As healthcare systems in resource-limited sectors expand, our findings serve as a reference point. Continued training and quality improvement studies can further enhance ERCP effectiveness in the region and beyond.
Read morePathological fondness for noises with right temporal lobe atrophy.
Impact of a digitally enabled, time-restricted eating weight management program, the Roczen program, on eating behaviors, depression symptoms and health related quality of life.
Spontaneous Resolution of Miliary Pulmonary Nodules Following Intravesical Bacillus Calmette-Guérin (BCG) Therapy: A Case Report and Literature Review
Intravesical Bacillus Calmette-Guérin (BCG) immunotherapy is a well-established treatment for non-muscle-invasive bladder cancer. Although it is typically associated with local irritative symptoms, rare systemic and pulmonary complications can occur, including hypersensitivity pneumonitis and miliary tuberculosis.We report the case of a 70-year-old man who developed diffuse miliary pulmonary micronodules and ground-glass opacities after his 12th BCG instillation. Despite imaging findings suggestive of disseminated infection, the patient remained clinically stable, without fever, hypoxia, or systemic deterioration. Bronchoalveolar lavage cultures were negative for Mycobacterium bovis. A shared decision was made to withhold antimycobacterial therapy and monitor closely. Follow-up imaging revealed spontaneous improvement without treatment.This case underscores that observation may be appropriate in selected stable patients without systemic signs of infection. Careful clinical assessment and individualized management are essential to avoid unnecessary therapy and ensure patient safety.
Read more